Optimer Wins U.S. Approval for Drug to Fight Fatal Bacteria
This article is for subscribers only.
Optimer Pharmaceuticals Inc. won U.S. approval for the first antibiotic in a quarter-century that fights a deadly bacterium linked to intestinal infections often caught in hospitals.
The Food and Drug Administration cleared fidaxomicin, the agency said today in a statement. Optimer will sell the drug under the name Dificid.